Migraines and Serotonin Receptor Agonists
Links shared publicly online about this topic
Neurology Medical News about Migraine Disorders 5-HT1F Receptor Agonists
mdlinx.com — “5-HT1F Receptor Agonists: A New Treatment Option for Migraine Attacks?” View full resource at mdlinx.com
Most Recently Shared on May 4, 2010 at 7:03 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
5-HT1F Receptor Agonists: A New Treatment Option for Migraine Attacks?: Neurotherapeutics http://bit.ly/cCBPff #neurology #mdlinx
Medical News: AAN: Glutamate Receptor Inhibitors May Help Migraine - in Meeting Coverage, AAN from MedPage Today
medpagetoday.com — “SEATTLE -- Inhibition of glutamate receptors may play a role in migraine treatment, researchers here said.” View full resource at medpagetoday.com
Most Recently Shared on April 30, 2009 at 4:35 pm By:
AAN: Glutamate Receptor Inhibitors May Help Migraine http://medpagetoday.com/13992
Sumavel DosePro available for acute migraine and cluster headache - MPR
empr.com — “Zogenix and Astellas have made available Sumavel DosePro (sumatriptan injection), a selective 5-HT1B/1D receptor agonist in a needle-free delivery system, for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache episodes.” View full resource at empr.com
Most Recently Shared on January 13, 2010 at 4:23 pm By:
MPR News: Sumavel DosePro available for acute migraine and cluster headache: Zogenix and Astellas have made availa... http://bit.ly/7bcgpL
Alsuma Auto-Injector available for acute migraine and cluster headache - MPR
empr.com — “Meridian Medical has made available Alsuma (sumatriptan injection auto-injector), a selective 5-HT1B/1D receptor agonist, for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache episodes.” View full resource at empr.com
Most Recently Shared on December 7, 2010 at 5:26 pm By:
MPR News: Alsuma Auto-Injector available for acute migraine and cluster headache: Meridian Medical has made avai... http://bit.ly/eTM00A
CoLucid's lasmiditan NAAMA effective in treatment of acute migraine attacks
news-medical.net — “CoLucid Pharmaceuticals, Inc.,, an innovative biotechnology company focusing on therapies for central nervous system disorders, today announced that its investigational first-in-class Neurally Acting Anti-Migraine Agent (NAAMA), lasmiditan (also known as COL-144), a selective 5-HT1F receptor agonist, was effective when given orally to treat acute migraine attacks, as documented in a Phase IIb study.” View full resource at news-medical.net
Most Recently Shared on June 10, 2010 at 7:50 am By:
Stroke News: CoLucid's lasmiditan NAAMA effective in treatment of acute migraine attacks: CoLucid Pharmaceutical... http://twurl.nl/e17gwo
Sumavel DosePro approved for acute migraine and cluster headache - MPR
empr.com — “The FDA has approved Sumavel DosePro (sumatriptan injection, from Zogenix and Astellas), a selective 5-HT1B/1D receptor agonist in a needle-free delivery system, for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache episodes.” View full resource at empr.com
Most Recently Shared on July 16, 2009 at 3:42 pm By:
MPR News: Sumavel DosePro approved for acute migraine and cluster headache: The FDA has approved Sumave.. http://bit.ly/19OwVS
BLOSSOM study
theheart.org — “Among overweight patients, including those with preexisting echocardiographic valvulopathy, the average weight loss was approximately 5 kg with lorcaserin. Importantly, there were no concerns raised about new or worsening cardiac valve problems with the 5HT2C-receptor agonist.” View full resource at theheart.org
Most Recently Shared on October 27, 2009 at 8:46 pm By:
heartwire: Lorcaserin passes weight-loss and valvular hurdles in BLOSSOM study http://bit.ly/4ttPu7
Clinical Data, Inc. Announces Approval Of Generic Name Vilazodone, First In A New Class Of Experimental Treatments For Depression
medicalnewstoday.com — “Clinical Data, Inc. (NASDAQ: CLDA) announced today that the United States Adopted Name Council (USAN) has approved the generic name vilazodone hydrochloride.” View full resource at medicalnewstoday.com
Most Recently Shared on June 22, 2009 at 4:01 pm By:
psychiatryrounds Support and Psychiatry
Clinical Data, Inc. Announces Approval Of Generic Name Vilazodone, First In A New Class Of Experimental Treatmen.. http://tinyurl.com/laprw7
NEJM -- Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management
content.nejm.org — “Original Article from The New England Journal of Medicine -- Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management” View full resource at content.nejm.org
Most Recently Shared on July 20, 2010 at 2:45 pm By:
William Yates, M.D. Family Medicine Doctor, Physician, Doctor, and Psychiatrist
Selective serotonin 2C receptor agonist drug (lorcaserin) effective for weight loss. http://ht.ly/2dtgf
Lorcaserin and obesity
theheart.org — “In addition to the weight loss with the selective serotonin 2C receptor agonist, an assessment of adverse events at one and two years did not show any difference in the rates of cardiac valvulopathy, a problem that was observed with less selective obesity agents, report investigators.” View full resource at theheart.org
Most Recently Shared on July 14, 2010 at 9:19 pm By:
Significant weight loss in obese and overweight patients treated with lorcaserin: In addition to the weight loss w... http://bit.ly/aDVABp
Lorcaserin induced significant weight loss, weight management
endocrinetoday.com — “Lorcaserin, a selective serotonin 2C receptor agonist, was associated with significant weight loss and improved maintenance of weight loss compa” View full resource at endocrinetoday.com
Most Recently Shared on July 20, 2010 at 6:30 pm By:
Lorcaserin induced significant weight loss, weight management http://ow.ly/2dYXv
FDA rejects lorcaserin
endocrinetoday.com — “The FDA has completed its review of the New Drug Application for lorcaserin, an investigational selective serotonin 2C receptor agonist, and det” View full resource at endocrinetoday.com
Most Recently Shared on October 26, 2010 at 2:28 pm By:
FDA rejects lorcaserin http://bit.ly/bDsV0g
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
-
MedPage Today
Daily, peer reviewed medical news for clinicians
-
MPR
eMPR.com provides up-to-date, concise drug information at the point-of-care.
Advertisement
